Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MK0966
rofecoxib · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| rofecoxib | DRUG | - |
| Comparator: placebo (unspecified) | DRUG | - |
Regular PSA testing and study biopsies required.
Top 20 of 55 competitors
Rofecoxib is a small molecule drug developed by Merck & Company, Inc. (ticker MRK) that has been studied in oncology, specifically for prostate cancer. It is a PTGS2 inhibitor. The compound is identified in ChEMBL as CHEMBL122 and has been evaluated in a Phase 3 clinical trial.
Rofecoxib was studied for the prevention of prostate cancer. The Phase 3 trial NCT00060476, titled Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201), enrolled 15,000 male participants aged 50 years and older. The study is completed, and rofecoxib remains an investigational agent in this setting.
Rofecoxib targets PTGS2, also known as cyclooxygenase-2. It acts as an inhibitor of this enzyme. PTGS2 inhibition is the mechanism attributed to rofecoxib in its clinical development for prostate cancer prevention, as studied by Merck in the Phase 3 trial NCT00060476.
Rofecoxib was developed by Merck & Company, Inc., which trades under the ticker MRK. Merck sponsored the Phase 3 prostate cancer prevention study of rofecoxib, registered as NCT00060476 under the code MK0966. The company is the developer associated with this asset.
Rofecoxib reached Phase 3 clinical development for prostate cancer. The single registered trial, NCT00060476, was a Phase 3 study that has been completed, with no active trials currently listed. Rofecoxib is an investigational drug in this oncology indication rather than an approved prostate cancer therapy.
Rofecoxib was evaluated in one clinical trial, NCT00060476, titled Treatment With MK0966 for the Prevention of Prostate Cancer (0966-201). This Phase 3 study was randomized and double blind, enrolled 15,000 male participants aged 50 and older, and is now completed. No active trials are listed.